%PDF-1.4
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
uuid:6bea6575-2216-0147-be85-be3e39285aec
adobe:docid:indd:24632813-a640-11e5-9294-f7950737992f
xmp.id:9999A33C42206811822A9A24F1259094
proof:pdf
xmp.iid:802C1CD928206811822A9A24F1259094
xmp.did:CD910B7D11206811822ABF5917DAB9A5
adobe:docid:indd:24632813-a640-11e5-9294-f7950737992f
default
converted
from application/x-indesign to application/pdf
Adobe InDesign CS6 (Macintosh)
/
2017-03-17T18:48:40+08:00
2017-03-17T18:48:40+08:00
2017-03-17T18:48:40+08:00
2017-03-17T18:48:40+08:00
Adobe InDesign CS6 (Macintosh)
application/pdf
Adobe PDF Library 10.0.1
False
endstream
endobj
5 0 obj
<>
endobj
3 0 obj
<>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/TrimBox[14.1732 14.1732 536.173 761.123]/Type/Page>>
endobj
8 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[14.1732 14.1732 536.173 761.123]/Type/Page>>
endobj
9 0 obj
<>/Font<>/ProcSet[/PDF/Text/ImageB]/XObject<>>>/TrimBox[14.1732 14.1732 536.173 761.123]/Type/Page>>
endobj
10 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[14.1732 14.1732 536.173 761.123]/Type/Page>>
endobj
11 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/TrimBox[14.1732 14.1732 536.173 761.123]/Type/Page>>
endobj
31 0 obj
<>stream
BT
0 0 0 1 k
/GS0 gs
/T1_0 1 Tf
10 0 0 10 471.6732 38.3033 Tm
(13)Tj
0.005 Tc 0.218 Tw -40.05 66.1 Td
[(Re)14.9(g)4.9(ardless of the initial symptoms, the entire)5( )]TJ
0.053 Tw 0 -1.15 TD
[(brachial ple)14.9(xus, from the roots to the peripheral)5( )]TJ
-0.001 Tc -0.075 Tw T*
[(nerv)14.7(es, may be in)39.6(v)19.5(olv)14.6(ed. )17.6(Therefore, clinicians and)-1( )]TJ
0.005 Tc 0.09 Tw T*
[(specialists in electrodiagnostic medicine should)5( )]TJ
0.192 Tw T*
[(carefully e)24.9(v)25(aluate the entire brachial ple)14.9(xus if)5( )]TJ
0.01 Tc 0.3 Tw T*
[(neuralgic amyotroph)4.6(y is suspected.There has)10( )]TJ
0.019 Tc T*
[(been anecdotal e)25(vidence that corticosteroids)19( )]TJ
0.005 Tc 0.142 Tw T*
[(ha)19.8(v)14.9(e a f)9.8(a)19.7(v)19.8(orable ef)24.9(fect on pain and reco)14.9(v)14.9(ery)64.9(.)]TJ
0 Tc 0 Tw 5.83 0 0 5.83 261.8141 622.1332 Tm
[(1)-5(2 )]TJ
0.005 Tc 0.268 Tw 10 0 0 10 71.1732 607.3032 Tm
[(There is need for proper clinical randomized)5.1( )]TJ
0.09 Tw T*
[(trial to e)24.9(v)24.9(aluate the ef)24.9(fecti)24.9(v)14.9(eness of the v)25(arious)5( )]TJ
0.001 Tc -0.075 Tw T*
[(therapeutic interv)14.9(ention for functional reco)14.9(v)15(ery in)1( )]TJ
-0.005 Tc T*
[(neuralgic amyotroph)4.8(y)64.9(. One randomized controlled)-5( )]TJ
0.046 Tc 0.3 Tw T*
[(trial comparing prednisolone to placebois)46( )]TJ
0.005 Tc 0.05 Tw T*
[(currently a)14.9(w)9.8(aiting formal reporting.)]TJ
-0.005 Tw 5.83 0 0 5.83 218.0851 553.1332 Tm
(12)Tj
0 Tc 0 Tw /Span<>> BDC
-25.199 -1.973 Td
( )Tj
EMC
0.005 Tc 0.166 Tw 10 0 0 10 83.1732 538.3032 Tm
[(Our study had se)25(v)14.9(eral limitations. First, we)5( )]TJ
0.181 Tw -1.2 -1.15 Td
[(had no follo)24.9(w-up data )0.5(obtained later than one)5( )]TJ
0.007 Tc 0.3 Tw T*
[(year after disease onset; long-term outcomes)7( )]TJ
0.005 Tc 0.034 Tw T*
[(were )0.5(thus )0.6(not )0.6(addressed. )0.5(Ho)24.9(we)25(v)14.9(er)39.8(, )0.6(patients )0.6(who)5( )]TJ
0.28 Tw T*
[(e)14.9(xperience mark)9.8(ed impro)14.9(v)14.9(ements may decide)5( )]TJ
0.016 Tc 0.3 Tw T*
[(not to k)9.6(eep hospital appointments. )29.6(W)79.7(e thus)16( )]TJ
0.005 Tc 0.051 Tw T*
[(decided to e)24.9(v)24.9(aluate the 1-year follo)24.9(w-up data to)5( )]TJ
0.197 Tw T*
[(e)14.9(xclude selection bias. Second, our study w)9.8(as)5.1( )]TJ
0.098 Tw T*
[(retrospecti)24.9(v)14.9(e in nature; we cannot contrib)19.7(ute to)5( )]TJ
0.141 Tw T*
[(the recent debate on disease incidence. Only a)5( )]TJ
0.152 Tw T*
[(small proportion of the patients re)25(v)14.9(ealed some)5( )]TJ
0.007 Tw T*
[(precipitating f)9.8(actors. It may be due to recall bias)5( )]TJ
-0.044 Tw T*
[(or limitation of retrospecti)24.9(v)14.9(e study design. )17.7(Third,)5( )]TJ
0.127 Tw T*
[(our number of subjects w)9.8(as small, because the)5( )]TJ
0.041 Tw T*
[(disease is relati)24.9(v)14.9(ely rare. Ho)24.9(we)25(v)14.9(er)39.8(, we e)14.9(xcluded)5( )]TJ
0 Tw T*
[(diabetes, since diabetes can greatly in\036uence the)5( )]TJ
-0.001 Tw T*
(results of electrodiagnostictest.)Tj
-0.005 Tw 5.83 0 0 5.83 196.9547 357.6332 Tm
(13 )Tj
-0.001 Tw 10 0 0 10 204.2208 354.3032 Tm
[(This enabled us)5( )]TJ
0.05 Tw -13.305 -1.15 Td
[(to ha)19.8(v)14.9(e more e)14.9(xact electrodiagnostic data.)]TJ
0.024 Tw /Span<>> BDC
T*
( )Tj
EMC
1.2 0 Td
[(In conclusion, painless weakness as an initial)5( )]TJ
0.019 Tw -1.2 -1.15 Td
[(symptom of neuralgic amyotroph)4.9(y may be more)5( )]TJ
-0.038 Tw T*
[(common than pre)25(viously thought. Of all patients,)5( )]TJ
0.084 Tw T*
[(70% e)14.9(xperienced f)9.8(a)19.8(v)19.7(orable outcomes by 1 year)5( )]TJ
0.05 Tw T*
(after disease onset.)Tj
/TT0 1 Tf
0 Tc 0 Tw 0 -2.35 TD
(DISCLOSURES)Tj
/T1_0 1 Tf
0.005 Tc 0.05 Tw 0 -1.75 TD
(Financial support: None)Tj
/C2_0 1 Tf
-0.005 Tw 0 -2.3 TD
[<00260052005100C0004C004600570003>-50<005200490003>-50<002C0051005700480055004800560057001D0003>-50<0031005200510048>5.2<0003>]TJ
/TT0 1 Tf
0 Tc 0 Tw 0 -2.35 TD
(REFERENCES)Tj
/T1_0 1 Tf
0.006 Tc 0.3 Tw /Span<>> BDC
8.5 0 0 8.5 71.1732 181.8032 Tm
( )Tj
EMC
0.652 0 Td
[(1)1(.)]TJ
/Span<>> BDC
0.76 0 Td
( )Tj
EMC
0.706 0 Td
[(Sathasi)25.2(v)25.2(am S, Leck)15.2(y B, Manohar R, Selv)25.2(an )55.2(A.)6( )]TJ
0.035 Tc 0 -1.176 TD
[(Ne)0.5(ura)0.5(lgic)0.5( a)0.5(myot)0.5(roph)5.3(y)65.4(.)]TJ
/T1_1 1 Tf
[( )0.5(J Bo)0.5(ne )0.5(J)25.3(oi)0.5(nt S)0.5(ur)37.3(g B)0.5(r)35( )]TJ
/T1_0 1 Tf
0.005 Tc -0.005 Tw T*
(2008;90:550-3.)Tj
0.211 Tw /Span<>> BDC
-2.118 -1.176 Td
( )Tj
EMC
0.652 0 Td
(2.)Tj
/Span<>> BDC
( )Tj
EMC
1.466 0 Td
[(Moriguchi K, Miyamoto K, )17.9(T)79.9(akada K, K)15(usunoki)5( )]TJ
0.096 Tw T*
[(S. )0.5(F)14.9(our cases of anti-g)4.8(anglioside )0.5(antibody-positi)24.9(v)14.9(e)5( )]TJ
0.04 Tc 0.3 Tw T*
[(neuralgic amyotroph)4.8(y with good response to)40( )]TJ
0.014 Tc T*
[(intra)19.9(v)15(enous immunoglob)20(ulin infusion therap)9.9(y)65.1(.)]TJ
/T1_1 1 Tf
0 Tc 0.314 Tw ( J )Tj
0.005 Tc -0.005 Tw T*
[(Neur)45(oimmunol )]TJ
/T1_0 1 Tf
6.32 0 Td
(2011;238:107-9.)Tj
0.132 Tw /Span<>> BDC
-8.438 -1.176 Td
( )Tj
EMC
0.652 0 Td
(3.)Tj
/Span<>> BDC
( )Tj
EMC
1.466 0 Td
[(Suarez GA, Giannini C, Bosch EP)110.8(, )]TJ
/T1_1 1 Tf
(et al)Tj
/T1_0 1 Tf
[(. Immune)5.1( )]TJ
0.007 Tw 0 -1.176 TD
[(brachial ple)14.9(xus neuropath)4.9(y: suggesti)24.9(v)14.9(e e)24.9(vidence for)5.1( )]TJ
0.168 Tw 0 -1.176 TD
(an in\036ammatory-immune pathogenesis.)Tj
/T1_1 1 Tf
[( Neur)44.9(olo)9.8(gy)5( )]TJ
/T1_0 1 Tf
-0.005 Tw 25.235 72.785 Td
(1996;46:559-61.)Tj
0.016 Tc 0.3 Tw /Span<>> BDC
-2.118 -1.176 Td
( )Tj
EMC
0.652 0 Td
[(4)11(.)]TJ
/Span<>> BDC
0.76 0 Td
( )Tj
EMC
0.706 0 Td
[(Cruz-Martinez )55.2(A, Barrio M, )55.3(Arpa J. Neuralgic)16( )]TJ
0.005 Tc 0.186 Tw T*
[(amyotroph)4.8(y: )0.5(v)24.9(ariable )0.5(e)14.9(xpression )0.5(in )0.5(40 )0.5(patients.)]TJ
/T1_1 1 Tf
0 Tc 0.191 Tw [( )0.5(J )]TJ
0.005 Tc 0.05 Tw T*
[(P)79.8(eripher Nerv Syst )]TJ
/T1_0 1 Tf
-0.005 Tw (2002;7:198-204.)Tj
-0.042 Tw /Span<>> BDC
-2.118 -1.176 Td
( )Tj
EMC
0.652 0 Td
(5.)Tj
/Span<>> BDC
( )Tj
EMC
1.466 0 Td
[(v)24.9(an )55.5(Alfen )0.6(N, )0.5(v)24.9(an )0.6(Engelen )0.6(BG. )18.3(The )0.5(clinical )0.5(spectrum)5( )]TJ
0.034 Tc 0.3 Tw T*
[(of neuralgic amyotroph)5.2(y in 246 cases.)]TJ
/T1_1 1 Tf
[( Br)15.1(ain)34( )]TJ
/T1_0 1 Tf
0.005 Tc -0.005 Tw T*
(2006;129:438-50.)Tj
0.087 Tw /Span<>> BDC
-2.118 -1.176 Td
( )Tj
EMC
0.652 0 Td
(6.)Tj
/Span<>> BDC
( )Tj
EMC
1.466 0 Td
[(V)110.8(an )0.6(Eijk )0.5(JJ, )0.6(Groothuis )0.5(JT)74(, )50.4(V)110.8(an )55.5(Alfen )0.6(N. )0.6(Neuralgic)5( )]TJ
-0.01 Tc -0.106 Tw T*
[(a)0.6(m)0.5(y)0.6(o)0.5(t)0.5(r)0.6(o)0.5(p)0.6(h)5.4(y)0.5(:)0.6( )54.8(A)0.6(n)0.5( u)0.6(p)0.5(d)0.5(a)0.6(t)0.5(e)0.6( o)0.6(n)0.5( d)0.6(i)0.5(a)0.6(g)0.5(n)0.5(o)0.6(s)0.5(i)0.6(s)0.5(,)0.6( p)0.5(a)0.6(t)0.5(h)0.6(o)0.5(p)0.6(h)5.4(y)0.5(s)0.6(i)0.5(o)0.6(l)0.5(o)0.5(g)0.6(y)65.5(,)-10( )]TJ
0.005 Tc 0.05 Tw T*
(and treatment.)Tj
/T1_1 1 Tf
( Muscle Nerve )Tj
/T1_0 1 Tf
-0.005 Tw (2016;53:337-50.)Tj
0.284 Tw /Span<>> BDC
-2.118 -1.176 Td
( )Tj
EMC
0.652 0 Td
(7.)Tj
/Span<>> BDC
( )Tj
EMC
1.466 0 Td
(Cup EH, Ijspeert J, Janssen RJ, )Tj
/T1_1 1 Tf
(et al)Tj
/T1_0 1 Tf
[(. Residual)5( )]TJ
0.148 Tw T*
[(complaints after neuralgic amyotroph)4.9(y)65(.)]TJ
/T1_1 1 Tf
0.131 Tw [( )0.5(Ar)36.9(c)14.9(h )-17.3(Phys)5( )]TJ
0.05 Tw T*
(Med Rehabil )Tj
/T1_0 1 Tf
-0.005 Tw (2013;94:67-73.)Tj
-0.034 Tw /Span<>> BDC
-2.118 -1.176 Td
( )Tj
EMC
0.652 0 Td
(8.)Tj
/Span<>> BDC
( )Tj
EMC
1.466 0 Td
[(v)24.9(an )54.6(Alfen N, v)25(an Eijk JJ, Ennik )17.5(T)74(, )]TJ
/T1_1 1 Tf
(et al)Tj
/T1_0 1 Tf
[(. Incidence of)5( )]TJ
-0.037 Tw T*
[(neuralgic amyotroph)4.9(y \(P)14.9(arsonage )17.6(T)45(urner syndrome\))5( )]TJ
-0.046 Tw T*
[(in a primary care setting--a prospecti)24.9(v)14.9(e cohort study)64.9(.)]TJ
/T1_1 1 Tf
0 Tc 0 Tw 21 0 Td
( )Tj
0.005 Tc 0.05 Tw -21 -1.176 Td
(PLoS One )Tj
/T1_0 1 Tf
-0.005 Tw (2015;10:e0128361.)Tj
-0.04 Tw /Span<>> BDC
-2.118 -1.176 Td
( )Tj
EMC
0.652 0 Td
(9.)Tj
/Span<>> BDC
( )Tj
EMC
1.466 0 Td
[(MacDonald BK, Cock)9.8(erell OC, Sander JW)91.8(, Shorv)19.8(on)5( )]TJ
0.026 Tc 0.3 Tw T*
[(SD. )17.5(The incidence and lifetime pre)24.6(v)24.5(alence of)26.1( )]TJ
0.005 Tc 0.032 Tw T*
[(neurological disorders in a prospecti)24.9(v)14.9(e community-)]TJ
-0.002 Tc -0.075 Tw T*
(based study in the UK.)Tj
/T1_1 1 Tf
[( Br)15.1(ain )]TJ
/T1_0 1 Tf
(2000;123 \( Pt 4\):665-76.)Tj
-0.007 Tc /Span<>> BDC
-2.118 -1.176 Td
( )Tj
EMC
0.147 0 Td
[(1)-12(0)-12(.)]TJ
/Span<>> BDC
1.265 0 Td
( )Tj
EMC
0.706 0 Td
[(v)25.2(an )55.2(Alfen N. Clinical and pathoph)5.2(ysiological concepts)-7( )]TJ
-0.003 Tc T*
[(of neuralgic amyotroph)5.2(y)65.4(.)]TJ
/T1_1 1 Tf
[( Nat Re)15.2(v Neur)45.3(ol )]TJ
/T1_0 1 Tf
0.003 Tw (2011;7:315-)Tj
0.005 Tc -0.005 Tw T*
(22.)Tj
0.079 Tw /Span<>> BDC
-2.118 -1.176 Td
( )Tj
EMC
0.147 0 Td
(11.)Tj
/Span<>> BDC
( )Tj
EMC
1.971 0 Td
[(Tsairis P)110.8(, Dyck PJ, Mulder D)29.8(W)91.9(. Natural history of)5( )]TJ
0.113 Tw T*
[(brachial ple)14.9(xus neuropath)4.9(y)65(. Report on 99 patients.)]TJ
/T1_1 1 Tf
0 Tc 0 Tw 21 0 Td
( )Tj
0.005 Tc 0.05 Tw -21 -1.176 Td
[(Ar)36.9(c)14.9(h Neur)44.9(ol )]TJ
/T1_0 1 Tf
-0.005 Tw (1972;27:109-17.)Tj
-0.002 Tc -0.075 Tw /Span<>> BDC
-2.118 -1.176 Td
( )Tj
EMC
0.147 0 Td
[(1)-7(2)-7(.)]TJ
/Span<>> BDC
1.265 0 Td
( )Tj
EMC
0.706 0 Td
[(v)25(an )55(Alfen N, v)25(an Engelen BG, Hughes RA. )17.8(T)35(reatment)-2( )]TJ
0.005 Tc 0.058 Tw T*
[(for idiopathic and hereditary neuralgic amyotroph)4.9(y)5( )]TJ
-0.006 Tc -0.075 Tw T*
(\(brachial neuritis\).)Tj
/T1_1 1 Tf
[( Coc)14.8(hr)14.9(ane Database Syst Re)14.8(v )]TJ
/T1_0 1 Tf
0.006 Tw [(2009;)-6( )]TJ
0.003 Tc -0.003 Tw T*
(doi:10.1002/14651858.CD006976.pub2.CD006976.)Tj
0.029 Tc 0.3 Tw /Span<>> BDC
-2.118 -1.176 Td
( )Tj
EMC
0.147 0 Td
[(1)24(3)24(.)]TJ
/Span<>> BDC
1.265 0 Td
( )Tj
EMC
0.706 0 Td
[(Im S, Kim SR, P)14.9(ark JH, Kim )89.8(YS, P)14.9(ark GY)128.9(.)29( )]TJ
0.005 Tc 0.104 Tw T*
[(Assessment of the medial dorsal cutaneous, dorsal)5( )]TJ
-0.018 Tw T*
[(sural, and medial plantar nerv)14.9(es in impaired glucose)5( )]TJ
-0.056 Tw T*
[(tolerance and diabetic patients with normal sural and)5( )]TJ
0.007 Tw T*
[(super\037cial peroneal nerv)14.9(e responses.)]TJ
/T1_1 1 Tf
[( Diabetes Car)36.8(e)5.1( )]TJ
/T1_0 1 Tf
-0.005 Tw T*
(2012;35:834-9.)Tj
ET
endstream
endobj
24 0 obj
<>
endobj
14 0 obj
<>
endobj
15 0 obj
<>
endobj
18 0 obj
<>
endobj
40 0 obj
<>
endobj
41 0 obj
<>stream
H\n0yCi%4V(1(o?;:i_$Xnѻ
gvzoP_9I>羚GQqL3ke:i~zW*z}髨V:n=Y:ϵŖ>Ru:
ez7/k\FIoD,NcݠUuv+tv+eNc
*mS Sy/g>(|d> $I`
C*);lS |||||F0???????????34|Fbx/Fq3fͰR˺
_u~Ds!`KaTŏ`
endstream
endobj
42 0 obj
<>stream
H XTGͫAP@љfJX!]n"!"**$AcxrxQAÓ<;췟_z~z `AquyLBc3BVU /Ӂq/@1)